![]() |
COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. | ![]() |
University of Cambridge > Talks.cam > HDR UK Cambridge Seminar Series > Genetics for drug discovery, going beyond target ID
![]() Genetics for drug discovery, going beyond target IDAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Spencer Keene. Please sign up at: https://www.ticketsource.co.uk/university-of-cambridge/genetics-for-drug-discovery-going-beyond-target-id-joanna-mccammond-mcgill-howson/e-raprpr At Novo Nordisk, we have a human centric approach to drug discovery, for example by harnessing human genetics and integrating other omics and data types to identify potential targets in cardiometabolic diseases. That targets with human genetics support are more likely to be successful in clinical development, is well established. What is less often discussed is, can we further leverage human data to help develop therapies for patients? I will highlight a few examples of what we are thinking about in relation to using human genetics at Novo Nordisk, beyond target identification. This talk is part of the HDR UK Cambridge Seminar Series series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsLife Sciences & Society ‘Geographies of Radical Difference’ Cambridge Journal of Regions, Economy and SocietyOther talksFace Learning in People with Developmental Prosopagnosia and “Super-Recognisers" Lawvere Theories in Lean Practitioner Series: Comfort Ero STING and inflammatory disease: insights from monogenic conditions Annual General Meeting 2024 Title TBC |